Edwards Lifesciences Reports First Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/10/2026
- S&P 500, Dow futures attempt recovery ahead of inflation report
- Oracle raises full year profit guidance, stock rises after hours
- Oil surges 6%, Brent and US crude both surpass $100 on more tanker attacks
- Analysts split on Apple after foldable iPhone Duo debut
- JPMorgan upgrades Meta on AI models and agents, sees 'meaningful headroom'
- S&P 500 ends down as oil tops $100 per barrel
- White House copper tariff plan stalls amid affordability concerns, sources say
- Trump promises $5,000 payout to U.S. adults if Republicans win election
- Crude Inventory 0.4M Barrels Last Week - EIA
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Edwards Lifesciences (EW) PT Lowered to $200 at Raymond James
April 24, 2019 8:58 AM EDTRaymond James analyst Jayson Bedford lowered the price target on Edwards Lifesciences (NYSE: EW) to $200.00 (from $210.00) while maintaining a Outperform rating.
... MoreEdwards Lifesciences (EW) PT Raised to $200 at Stifel
April 24, 2019 8:36 AM EDTStifel analyst Rick Wise raised the price target on Edwards Lifesciences (NYSE: EW) to $200.00 (from $190.00) while maintaining a Buy rating.
Overall Solid Start to 2019 Despite Underwhelming 1Q19 TAVR Growth... MoreEdwards Lifesciences (EW) PT Raised to $186 at RBC Capital
April 24, 2019 6:39 AM EDTRBC Capital analyst Brandon Henry raised the price target on Edwards Lifesciences (NYSE: EW) to $186.00 (from $182.00) while maintaining a Outperform rating following results.
... MoreEdwards Lifesciences (EW) Tops Q1 EPS by 10c; Raises Outlook
April 23, 2019 4:16 PM EDTEdwards Lifesciences (NYSE: EW) reported Q1 EPS of $1.32, $0.10 better than the analyst estimate of $1.22. Revenue for the quarter came in at $993 million versus the consensus estimate of $989.61 million.
GUIDANCE:
Edwards Lifesciences sees FY2019 EPS of $5.10-$5.35, from $5.05 to $5.30 and versus... More
